Arcellx Shares Rise Premarket on Expanded Gilead Collaboration
By Colin Kellaher
Shares of Arcellx jumped more than 10% in premarket trading Wednesday after the clinical-stage biotechnology company inked an extension of its collaboration with Gilead Sciences that includes a $200 million equity investment at a rich premium.
Gilead, which late last year invested $100 million for a nearly 7.2% stake in Arcellx, is buying an additional 3.24 million share at $61.68 each, 30% above Tuesday's closing price of $47.47 and nearly triple Arcellx's closing price of $21.68 on Dec. 8, 2022, the day before the companies unveiled their collaboration.
The new investment will raise Gilead's stake in Arcellx to around 13%, making it the Gaithersburg, Md., company's largest shareholder, according to FactSet data.
Arcellx shares were recently up 12% to $53.26 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 15, 2023 08:15 ET (13:15 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks